At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Early disclosure of genetic testing results +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Early disclosure of genetic testing results and Late disclosure of genetic testing results for Age-Related Macular Degeneration and 2 related conditions. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartAug 2022
Primary CompletionJul 2024
TodayJul 2026
First PostedMar 3, 2022
Enrollment StartAug 3, 2022
Primary CompletionJul 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.3 years ago
Interventions
Early disclosure of genetic testing resultsbehavioral
Early disclosure group receives results of genetic testing at Month 1
Late disclosure of genetic testing resultsbehavioral
Late disclosure group receives results of genetic testing at Month 12